VCG
Vantage Consulting Group Portfolio holdings
AUM
$5.73M
This Quarter Return
-3.05%
1 Year Return
-33.45%
3 Year Return
-18.66%
5 Year Return
–
10 Year Return
–
AUM
$575M
AUM Growth
+$575M
(+15%)
Cap. Flow
+$100M
Cap. Flow
% of AUM
17.39%
Top 10 Holdings %
Top 10 Hldgs %
88.96%
Holding
215
New
116
Increased
87
Reduced
5
Closed
4
Top Buys
| 1 |
Syntax Stratified LargeCap ETF
SSPY
|
$28.3M |
| 2 |
Royalty Pharma
RPRX
|
$24.5M |
| 3 |
Syntax Stratified US Total Market Hedged ETF
SHUS
|
$6.34M |
| 4 |
SMDY
Syntax Stratified MidCap ETF
SMDY
|
$3.41M |
| 5 |
SSLY
Syntax Stratified SmallCap ETF
SSLY
|
$1.7M |
Top Sells
| 1 |
L3Harris
LHX
|
$283K |
| 2 |
FLIR
FLIR Systems, Inc. (DE) Common Stock
FLIR
|
$274K |
| 3 |
HF Sinclair
DINO
|
$234K |
| 4 |
VG
Vonage Holdings Corporation
VG
|
$124K |
| 5 |
ANSS
Ansys
ANSS
|
$42.7K |
Sector Composition
| 1 | Healthcare | 79.29% |
| 2 | Technology | 2.06% |
| 3 | Consumer Staples | 1.97% |
| 4 | Consumer Discretionary | 1.69% |
| 5 | Energy | 0.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
Vertex Pharmaceuticals
VRTX
$103B
| $237K | 0.04% |
+1,177
| New | +$237K |
|
152
Analog Devices
ADI
$121B
| $234K | 0.04% |
+1,357
| New | +$234K |
|
153
Entergy
ETR
$39B
| $234K | 0.04% |
+2,345
| New | +$234K |
|
154
Hewlett Packard
HPE
$29.5B
| $234K | 0.04% |
16,036
+4,836
| +43% | +$70.6K |
|
155
Schlumberger
SLB
$53.6B
| $234K | 0.04% |
+7,304
| New | +$234K |
|
156
American International
AIG
$44.8B
| $232K | 0.04% |
+4,884
| New | +$232K |
|
157
Booking.com
BKNG
$178B
| $232K | 0.04% |
+106
| New | +$232K |
|
158
Incyte
INCY
$16.9B
| $232K | 0.04% |
+2,758
| New | +$232K |
|
159
Merck
MRK
$212B
| $232K | 0.04% |
+2,986
| New | +$232K |
|
160
NXP Semiconductors
NXPI
$57.8B
| $232K | 0.04% |
+1,126
| New | +$232K |
|
161
Seagate
STX
$35.9B
| $232K | 0.04% |
+2,642
| New | +$232K |
|
162
Eli Lilly
LLY
$657B
| $231K | 0.04% |
+1,008
| New | +$231K |
|
163
NOV
NOV
$4.87B
| $231K | 0.04% |
15,077
+4,322
| +40% | +$66.2K |
|
164
Organon & Co
OGN
$2.43B
| $231K | 0.04% |
+7,628
| New | +$231K |
|
165
Texas Instruments
TXN
$180B
| $231K | 0.04% |
+1,199
| New | +$231K |
|
166
Zoetis
ZTS
$67.5B
| $231K | 0.04% |
+1,242
| New | +$231K |
|
|
MXIM
167
DELISTED
Maxim Integrated Products
MXIM
| $230K | 0.04% |
+2,187
| New | +$230K |
|
168
Broadcom
AVGO
$1.4T
| $229K | 0.04% |
+481
| New | +$229K |
|
|
ALXN
169
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $229K | 0.04% |
+1,246
| New | +$229K |
|
170
Amgen
AMGN
$154B
| $228K | 0.04% |
+936
| New | +$228K |
|
171
Molson Coors Class B
TAP
$9.93B
| $228K | 0.04% |
+4,252
| New | +$228K |
|
172
Gilead Sciences
GILD
$140B
| $227K | 0.04% |
+3,300
| New | +$227K |
|
173
Johnson & Johnson
JNJ
$429B
| $226K | 0.04% |
+1,370
| New | +$226K |
|
174
Baker Hughes
BKR
$44.5B
| $225K | 0.04% |
+9,840
| New | +$225K |
|
175
Bristol-Myers Squibb
BMY
$96.5B
| $225K | 0.04% |
+3,366
| New | +$225K |
|